A modified staging classification for cutaneous T-cell lymphoma
Cutaneous T-cell lymphoma
is a cancer of the T-lymphocytes in the skin.
Cutaneous T-cell lymphomas
are a group of lymphomas characterized by abnormal accumulation of malignant T-cells in the skin, potentially resulting in the development of rashes, plaques and tumors.
The morphologic, immunohistochemical, and gene rearrangement studies supported the diagnosis of cutaneous T-cell lymphoma
is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma
Chidamide has demonstrated clinical efficacy in pivotal phase II trials on Cutaneous T-Cell Lymphoma
(CTCL) and Peripheral T-Cell Lymphoma (PTCL) conducted in China, and is currently undergoing phase II trial in NSCLC together with first line PC therapeutic treatment.
The company is also working with the University of Washington in a Phase II Merkel cell carcinoma trial and with UCSF for a Phase II cutaneous T-cell lymphoma
THERAKOS[R] UVAR XTS[R] Photopheresis System and the THERAKOS[R] CELLEX[R] Photopheresis System are approved for use in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma
(CTCL) that are unresponsive to other forms of treatment.
SAN DIEGO, May 26, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today it will initiate three Phase II clinical trials to assess its cancer-destroying, tissue-sparing ElectroImmunotherapy technology in patients with melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma
GlobalData's clinical trial report, Cutaneous T-Cell Lymphoma
Global Clinical Trials Review, H1, 2012" provides data on the Cutaneous T-Cell Lymphoma
clinical trial scenario.
HuMax-CD4 (Zanolimumab) is a fully human monoclonal anti-CD4 antibody for the targeted treatment of T-cell lymphomas, including cutaneous T-cell lymphoma
(CTCL) and peripheral T-cell lymphoma (PTCL).
a privately held specialty pharmaceutical company, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Ceptaris' investigational drug, chlormethine gel (also known as mechlorethamine gel in the US), for the treatment of Cutaneous T-Cell Lymphoma